HIPEC for Peritoneal Carcinomatosis
Phase II Trial of Cytoreduction + Hyperthermic Intraperitoneal Mitomycin-C+ Standard Systemic Therapy In Patients With Peritoneal Carcinomatosis
Sponsor: Albert Einstein College of Medicine
A PHASE2 clinical study on Appendiceal Cancer and Colorectal Cancer, this trial is completed. The trial is conducted by Albert Einstein College of Medicine and has accumulated 13 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Nov 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Recruiting → Completed
▶ Show 8 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Enrolling By Invitation → Recruiting
-
Dec 2019 — Jan 2020 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2019 — Dec 2019 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2018 — Feb 2019 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Enrolling By Invitation PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Einstein College of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .